Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer
S. Larry Goldenberg, Laurence H. Klotz, John R. Srigley et al. · The Journal of Urology · 1996
No AccessJournal of UrologyClinical Urology: Original Article1 Sep 1996Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer S. Larry Goldenberg, Laurence H. Klotz, John Srigley, Michael A.S. Jewett, David Mador, Yves Fradet, Jack Barkin, Joseph Chin, Jean-Marie Paquin, Martin J. Bullock, and Suzanne Laplante S. Larry GoldenbergS. Larry Goldenberg , Laurence H. KlotzLaurence H. Klotz , John SrigleyJohn Srigley , Michael A.S. JewettMichael A.S. Jewett , David MadorDavid Mador , Yves FradetYves Fradet , Jack BarkinJack Barkin , Joseph ChinJoseph Chin , Jean-Marie PaquinJean-Marie Paquin , Martin J. BullockMartin J. Bullock , and Suzanne LaplanteSuzanne Laplante View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65645-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A prospective, multicenter, randomized study was done to test the hypothesis that neoadjuvant androgen withdrawal decreases the incidence of positive margins following radical prostatectomy for localized prostate cancer. Materials and Methods: Observations were made of 213 patients randomized to undergo radical prostatectomy alone (101) or to receive a 12-week course of 300 mg. cyproterone acetate daily followed by surgery (112). Groups were similar at baseline in terms of clinical stage, serum prostate specific antigen and Gleason score. Of 192 patients available for efficacy analysis 9 had stage T1b, 8 stage T1c, 63 stage T2a, 36 stage T2b and 76 stage T2c disease. Results: One or more positive surgical margins were found in 59 of 91 patients (64.8 percent) in the surgery only group compared to 28 of 101 (27.7 percent) in the cyproterone acetate group (p = 0.001). Patients who received preoperative therapy had a statistically significantly lower rate of apical margin involvement than those who did not (17.8 versus 47.8 percent, respectively, p less than 0.0001). There was no statistically significant difference in surgical (p = 0.8645) or postoperative (p = 0.173) complications between the 2 groups. Conclusions: Neoadjuvant androgen withdrawal with a 12-week course of 300 mg. cyproterone acetate daily results in a lower rate of positive margins without adversely affecting postoperative recovery. The impact on patient survival will be determined by long-term followup. References 1 : Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J. Urol.1992; 148: 331. Link, Google Scholar 2 : Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant treatment. Urology1983; 21: 113. Google Scholar 3 : Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J. Urol.1990; 144: 1420. Link, Google Scholar 4 : Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J. Urol.1987; 138: 1407. Link, Google Scholar 5 : Surgical treatment of locally advanced (T3) prostatic carcinoma: early results. J. Urol.1987; 138: 816. Link, Google Scholar 6 : Adjuvant radiotherapy following radical prostatectomy: results and complications. J. Urol.1986; 135: 65. Link, Google Scholar 7 : Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology1988; 31: 191. Crossref, Medline, Google Scholar 8 : Serum prostatic specific antigen (PSA) in the management of patients after radical prostatectomy (RP). J. Urol., part 21988; 139: 314A. abstract 607. Google Scholar 9 : Radical prostatectomy for clinical stage T1-2 N0M0 prostatic adenocarcinoma: long-term results. J. Urol.1990; 144: 1180. Abstract, Google Scholar 10 : Theory and application of early systemic therapy. Sem. Oncol.1991; 18: 493. Google Scholar 11 : Editorial comment. J. Urol.1986; 135: 1205. Abstract, Google Scholar 12 : Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based on 25 years of experience. J. Urol.1969; 101: 86. Abstract, Google Scholar 13 : The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer—the Canadian perspective. Prog. Clin Biol. Res.1990; 359: 231. Google Scholar 14 : Effects of temporary antiandrogenic treatment prior to radical prostatectomy. In: Recent Advances in Urological Cancers. Diagnosis and Treatment. Edited by . Paris: Scientific Communications International, Ltd.1990. Google Scholar 15 : The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Amer. J. Surg. Path.1989; 13: 21. Google Scholar 16 : Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bN × M0) prostate cancer. J. Urol.1995; 154: 424. Abstract, Google Scholar 17 : Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol.1995; 154: 429. Link, Google Scholar 18 : Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate1994; 5: 9. Google Scholar 19 : Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin. Invest. Med.1993; 16: 516. Google Scholar 20 : Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med.1993; 16: 499. Google Scholar 21 : Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol.1993; 15
Cited by 130 works. doi:10.1016/s0022-5347(01)65645-3
Authors
- S. Larry Goldenberg
- Laurence H. Klotz
- John R. Srigley
- Michael A.S. Jewett
- David R. Mador
- Yves Fradet
- Jack Barkin
- Joseph L. Chin
- Jean-Marie Paquin
- Martin Joseph Bullock
- Suzanne Laplante
References
- Radical Prostatectomy for Clinical Stage T1-2N0M0 Prostatic Adenocarcinoma: Long-Term Results
- Understaging and undergrading of prostate cancer Argument for postoperative radiation as adjuvant therapy
- Adjuvant Radiotherapy Following Radical Prostatectomy: Results and Complications
- Frequency and Location of Extracapsular Extensionand Positive Surgical Margins in Radical Prostatectomy Specimens
- Analysis of Risk Factors Associated with Prostate Cancer Extension to the Surgical Margin and Pelvic Node Metastasis at Radical Prostatectomy
- Postoperative Radiotherapy for Patients with Carcinoma of the Prostate Undergoing Radical Prostatectomy with Positive Surgical Margins, Seminal Vesicle Involvement and/or Penetration Through the Capsule
- Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer
- Perioperative and Postoperative Complications from Bilateral Pelvic Lymphadenectomy and Radical Retropubic Prostatectomy
- The Prostatic Capsule
- Radical prostatectomy Patterns of local failure and survival in 67 patients